185 related articles for article (PubMed ID: 21992720)
1. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study.
Gater A; Abetz-Webb L; Battersby C; Parasuraman B; McIntosh S; Nathan F; Piault EC
Health Qual Life Outcomes; 2011 Oct; 9():88. PubMed ID: 21992720
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.
Clark MJ; Harris N; Griebsch I; Kaschinski D; Copley-Merriman C
Health Qual Life Outcomes; 2014 Jul; 12():104. PubMed ID: 24989428
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
4. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
[TBL] [Abstract][Full Text] [Related]
5. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
6. Content validity and ePRO usability of the BPI-sf and "worst pain" item with pleural and peritoneal mesothelioma.
Gelhorn HL; Eremenco S; Skalicky AM; Balantac Z; Cimms T; Halling K; Sexton C
J Patient Rep Outcomes; 2017; 2(1):16. PubMed ID: 29749970
[TBL] [Abstract][Full Text] [Related]
7. Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC® as Clinical Trial End Points.
Theodore-Oklota C; Bonner N; Spencer H; Arbuckle R; Chen CY; Skrinar A
Value Health; 2018 Aug; 21(8):973-983. PubMed ID: 30098676
[TBL] [Abstract][Full Text] [Related]
8. The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.
Mendoza TR; Dueck AC; Shi Q; Ma H; Zhang J; Qian Y; Cleeland CS
Eur J Pain; 2018 Mar; 22(3):565-571. PubMed ID: 29082574
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
12. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
14. Characterising the castration-resistant prostate cancer population: a systematic review.
Kirby M; Hirst C; Crawford ED
Int J Clin Pract; 2011 Nov; 65(11):1180-92. PubMed ID: 21995694
[TBL] [Abstract][Full Text] [Related]
15. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
Halabi S; Vogelzang NJ; Kornblith AB; Ou SS; Kantoff PW; Dawson NA; Small EJ
J Clin Oncol; 2008 May; 26(15):2544-9. PubMed ID: 18487572
[TBL] [Abstract][Full Text] [Related]
16. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.
De Vincentis G; Frantellizzi V; Follacchio GA; Farcomeni A; Pani A; Samaritani R; Schinzari G; Santini D; Cortesi E
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13112. PubMed ID: 31148330
[TBL] [Abstract][Full Text] [Related]
17. Measurement Properties of the Brief Pain Inventory-Short Form (BPI-SF) and Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) in Pain-related Musculoskeletal Conditions: A Systematic Review.
Jumbo SU; MacDermid JC; Kalu ME; Packham TL; Athwal GS; Faber KJ
Clin J Pain; 2021 Jun; 37(6):454-474. PubMed ID: 33734148
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Badrising SK; Louhanepessy RD; van der Noort V; Kieffer J; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam M; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; de Feijter JM; Dezentjé VO; Ras-van Spijk S; Vegt E; Haanen JB; van de Poll-Franse LV; Zwart W; Bergman AM
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):248-255. PubMed ID: 34446849
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
[TBL] [Abstract][Full Text] [Related]
20. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
